The Nose Knows: Tear Stimulation Strategies on the Horizon for Dry Eye Disease (Online CE Monograph)
Activity Description and Purpose
Increased understanding of the pathophysiology of dry eye disease (DED) over the past few decades has led to advances in its diagnosis and to new treatments, with a particular focus on medications for controlling inflammation. Dissatisfaction among both patients and eye care providers with anti-inflammatory modalities for managing DED, however, suggests the need for additional treatments. New and emerging therapies for DED are aimed at increasing natural tear production. In this educational activity, experts in DED present a review of natural tear production and its importance for ocular surface health, describe new and emerging tear stimulation treatments for DED, including data from pivotal trials, and share insights on therapeutic decision making through a series of case-based discussions.
This educational activity is intended for optometrists.
Upon completion of this activity, participants will be better able to:
- Review the benefits of natural tear production for ocular surface health
- Describe the mechanisms of actions of new and emerging tear stimulation treatments for dry eye disease
- Review the latest clinical trial data for new and emerging tear stimulation treatments for dry eye disease
- Identify patients who would be good candidates for tear stimulation treatments
|Paul Karpecki, OD, FAAO (Chair)|
University of Pikeville School of Optometry
Director, Cornea and External Disease
Kentucky Eye Institute and Gaddie Eye Centers
|Scott Hauswirth, OD, FAAO|
Assistant Professor of Ophthalmology
Director, Dry Eye Center of Colorado
University of Colorado Anschutz Medical Campus
|Kelly K. Nichols, OD, MPH, PhD, FAAO|
University of Alabama at Birmingham School of Optometry
|Patrick Vollmer, OD, FAAO|
Vita Eye Clinic
Shelby, North Carolina
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Scott Hauswirth, OD, is a consultant for Avedro, Inc, Dompé US, Inc, Glaukos Corporation, Horizon Therapeutics plc, Kala Pharmaceuticals, NuSight Medical, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc; is on the speakers bureau for Kala Pharmaceuticals and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Hovione, Nicox, Ocular Therapeutix, Inc, Sylentis, TearRestore, Inc, and TearSolutions; and has ownership interest (individual stocks) in Horizon Therapeutics plc, Oyster Point Pharma, Inc, and TearRestore, Inc.
Paul Karpecki, OD, receives royalties from Bausch & Lomb Incorporated; is a consultant for AbbVie Inc, Akorn, Inc, Alcon, Aldeyra Therapeutics, Allergan, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bio-Tissue, Bruder Healthcare, Bruno Vision, Dompé US, Inc, EyeGate, Eyenovia, Inc, Icare USA Inc, Imprimis Pharmaceuticals, Inc, Ivantis Inc, Kala Pharmaceuticals, Keplr Vision, Konan Medical USA, Inc, MacuLogix, Inc, Mallinckrodt, Mitotech, SA, Neurolens, Novartis Pharmaceuticals Corporation, OASIS Medical, OCULUS, Inc, Orasis Pharmaceuticals, Osmotica Pharmaceuticals plc, Oyster Point Pharma, Inc, Reichert, Inc, Rendia, Inc, RxSIGHT, ScienceBased Health, Sentiss Pharma Pvt Ltd, Sight Sciences, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearClear, and Vital Tears LLC; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Kala Pharmaceuticals, Mallinckrodt, Regeneron Pharmaceuticals, Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Bruno Vision, Lentechs, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, and Surface Pharmaceuticals Inc; and has ownership interest (future stock options) in AI Optics, Amros Pharmaceutical, BlephEx, Bruder Healthcare, Cambium Medical Technologies, Eyedaptic Inc, Eyedetec Medical, Gobiquity, Healthe Inc, Hue.AI, Ivantis Inc, iVeena Delivery Systems, Keplr Vision, LacriSciences LLP, LeGrande Corporation, Lentechs, Mati Therapeutics, Inc, Neurolens, OcuMedic, Ocuphire Pharma, Omega Ophthalmics, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Regener-Eyes, RxSIGHT, Sight Sciences, Silk Technologies Ltd, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearClear, TECLens, LLC, Visant Medical, Inc, and Visiology.
Kelly K. Nichols, OD, MPH, PhD, is a consultant for Acquiom, Alcon, Bruder Healthcare, Dompé US, Inc, Hanall Biopharma, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Osmotica Pharmaceuticals plc, Oyster Point Pharma, Inc, Shire, Sight Sciences, Takeda Pharmaceuticals USA, Inc, Tarsus Pharmaceuticals, Inc, Tear Film Innovations Inc, Thea Pharmaceuticals Limited, and TopiVert Ltd; receives fees for non-CME/CE services from Acquiom, Alcon, Bruder Healthcare, Dompé US, Inc, Hanall Biopharma, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Osmotica Pharmaceuticals plc, Oyster Point Pharma, Inc, Shire, Sight Sciences, Takeda Pharmaceuticals USA, Inc, Tarsus, Tear Film Innovations Inc, Thea Pharmaceuticals Limited, and TopiVert; and is a contracted researcher for Allergan, Kala Pharmaceuticals, and TearScience.
Patrick Vollmer, OD, has no relevant commercial relationships to disclose.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 73412-AS
COPE Course Category: Treatment & Management of Ocular Disease: Anterior Segment (AS)
Disclosure of Commercial Support
This continuing education activity is supported through an educational grant from Oyster Point Pharma, Inc.
Please refer to the official prescribing information for each drug and/or device discussed in this activity for approved indications, contraindications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry; MedEdicus LLC; Oyster Point Pharma, Inc; or Review of Optometry.
This CE activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 251
- 2.00 COPE
Clicking Register indicates that you have reviewed the CE information for this activity.
Learning Method and Medium
This educational activity consists of a supplement and twenty (20) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 2.0 hours to complete.